Skip to content

Evaluation of esketamine combined with remazolam for painless abortion and its effect on postoperative depression: a prospective, randomized, double-blind, parallel-controlled trial

Evaluation of esketamine combined with remazolam for painless abortion and its effect on postoperative depression: a prospective, randomized, double-blind, parallel-controlled trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100047190
Enrollment
Unknown
Registered
2021-06-10
Start date
2021-08-01
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Induced abortion

Interventions

Experimental groupA:Fentanyl + propofol
Experimental groupB:Esketamine + propofol
Experimental groupC:Fentanyl + Remazolam
Experimental groupD:Esketamine + Remazolam

Sponsors

Affiliated Hospital of Guizhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 45 years; ASA i- ii; BMI 18-28 kg /m^2; 2. Patients receiving painless abortion in the outpatient department; 3. Clearly understand and voluntarily participate in the study, and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with obvious respiratory and circulatory dysfunction, abnormal blood routine and blood biochemical indexes before surgery; 2. Suffering from severe neuropsychiatric diseases; 3. People suffering from infectious diseases; 4. Taking benzodiazepines or opioids intermittently every day for 1 month or for nearly 3 months; 5. Allergies or contrains to benzodiazepines, opioids, propofol and other drugs and their drug components; 6. Patients judged to have difficulty in airway management: modified Markov score iii or above; 7. Patients participating in other clinical trials; 8. Patients considered by the investigator to be inappropriate to participate in this study.

Design outcomes

Primary

MeasureTime frame
Success rate of operation;

Secondary

MeasureTime frame
Vital signs change;Induction time of anesthesia;Wake up of time;Departure standard time;Incidence of depression;

Countries

China

Contacts

Public ContactChen Jiejuan

Affiliated Hospital of Guizhou Medical University

2274860532@qq.com+86 13639136003

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026